Al-Dawaa Medical Services Company (4163.SR)
SAR 78.9
(-0.63%)
SAR 78.9
(-0.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 466.68 Million SAR | 26.46% |
| 2022 | 369.03 Million SAR | 37.76% |
| 2021 | 267.89 Million SAR | -32.69% |
| 2020 | 397.99 Million SAR | 32.4% |
| 2019 | 300.61 Million SAR | 1.98% |
| 2018 | 294.77 Million SAR | 40.13% |
| 2017 | 210.36 Million SAR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 130.49 Million SAR | 2.19% |
| 2024 Q2 | 134.29 Million SAR | 2.92% |
| 2023 Q2 | 122.04 Million SAR | 6.16% |
| 2023 Q1 | 114.96 Million SAR | -8.09% |
| 2023 FY | 466.69 Million SAR | 26.46% |
| 2023 Q4 | 127.69 Million SAR | 25.2% |
| 2023 Q3 | 101.99 Million SAR | -16.43% |
| 2022 Q4 | 125.08 Million SAR | 51.28% |
| 2022 Q3 | 82.68 Million SAR | -8.69% |
| 2022 Q2 | 90.55 Million SAR | 28.05% |
| 2022 Q1 | 70.71 Million SAR | -6.74% |
| 2022 FY | 369.03 Million SAR | 37.76% |
| 2021 Q3 | 50.8 Million SAR | -24.07% |
| 2021 Q2 | 66.91 Million SAR | -10.01% |
| 2021 Q4 | 75.82 Million SAR | 49.24% |
| 2021 FY | 267.89 Million SAR | -32.69% |
| 2021 Q1 | 74.35 Million SAR | -10.8% |
| 2020 Q2 | 131.66 Million SAR | 18.01% |
| 2020 FY | 397.99 Million SAR | 32.4% |
| 2020 Q4 | 83.35 Million SAR | 0.0% |
| 2020 Q3 | 83.35 Million SAR | -36.69% |
| 2020 Q1 | 111.56 Million SAR | 0.0% |
| 2019 FY | 300.61 Million SAR | 1.98% |
| 2018 FY | 294.77 Million SAR | 40.13% |
| 2017 FY | 210.36 Million SAR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 78.24 Million SAR | -496.411% |
| Nahdi Medical Company | 960.95 Million SAR | 51.435% |
| Al-Razi Medical Co. | 1.81 Million SAR | -25649.546% |
| Almujtama Alraida Medical Co. | 13.94 Million SAR | -3245.847% |